AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8294090 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy of esophageal varices (control group)
Number of subjects: 10
Study 30342299 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line AAD therapy
Number of subjects: 298
Study 30342299 — intervention group
Group type: COMPARATOR
Intervention: First-line cryoballoon-based pulmonary vein isolation
Number of subjects: 298
Study 27105981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic powered toothbrush
Number of subjects: 64
Study 27105981 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 64
Study 24969718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent drainage
Number of subjects: 149
Study 24969718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous drainage
Number of subjects: 149
Study 24969718 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional treatment and care)
Number of subjects: 149
Study 22643350 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg
Number of subjects: 379
Study 22643350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 379
Study 22643350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ETV + TDF)
Number of subjects: 379
Study 22643350 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 379
Study 20814005 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the early group (3 to 9 months post-stroke)
Number of subjects: 192
Study 20814005 — intervention group
Group type: COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the delayed group (15 to 21 months post-stroke)
Number of subjects: 192
Study 20814005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (early and delayed) received CIMT
Number of subjects: 192
Study 18514770 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine tumor-associated trypsin inhibitor (TATI)
Number of subjects: 160
Study 18514770 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21-1
Number of subjects: 160
Study 18514770 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bladder carcinoma antigen (UBC)
Number of subjects: 160
Study 18514770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 160
Study 18514770 — intervention group
Group type: EXPERIMENTAL
Intervention: TATI
Number of subjects: 160
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological and laboratory outcomes
Number of subjects: 199
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-important outcomes
Number of subjects: 199
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate outcomes
Number of subjects: 199
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory investigations
Number of subjects: 199
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprofit funding source
Number of subjects: 199
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Measure of physiological and laboratory outcomes
Number of subjects: 199
Study 16873788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over design
Number of subjects: 199
Study 12560298 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 3 microg x kg(‐1) followed by propofol 2 mg x kg(‐1) (Group I)
Number of subjects: 45
Study 12560298 — intervention group
Group type: COMPARATOR
Intervention: thiopentone 6 mg x kg(‐1) (Group II)
Number of subjects: 45
Study 12560298 — intervention group
Group type: COMPARATOR
Intervention: etomidate 0.3 mg x kg(‐1) (Group III)
Number of subjects: 45
Study 10868866 — intervention group
Group type: COMPARATOR
Intervention: intensive insulin therapy + placebo (C) (n = 12)
Number of subjects: 34
Study 10868866 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive insulin therapy + nicotinamide, 700 mg three times a day (NIC) (n = 11)
Number of subjects: 34
Study 10868866 — intervention group
Group type: EXPERIMENTAL
Intervention: 72‐h intravenous insulin followed by intensive insulin therapy + nicotinamide, 700 mg three times a day (NIV) (n = 11)
Number of subjects: 34
Study 9413735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.3 g (kg body mass)‐1) 3 h before exercise
Number of subjects: 6
Study 9413735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CaCO3)
Number of subjects: 6
Study 9413735 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO diet (81 +/‐ 2% CHO, 13 +/‐ 2% protein, 6 +/‐ 1% fat)
Number of subjects: 6
Study 9413735 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet (54 +/‐ 7% CHO, 13 +/‐ 2% protein, 33 +/‐ 7% fat)
Number of subjects: 6
Study 9413735 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate and placebo
Number of subjects: 6
Study 9413735 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental conditions
Number of subjects: 6
Study 9413735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 6
Study 8105519 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 35
Study 8105519 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 35
Study 8105519 — intervention group
Group type: COMPARATOR
Intervention: Inhaled terbutaline and salbutamol
Number of subjects: 35
Study 3517081 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 6
Study 3517081 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 6
Study 3517081 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and Diazepam combination
Number of subjects: 6
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-PDFF
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: SteatoTest
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: alanine aminotransferase ≥36 IU/L
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: NashTest
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroScan
Number of subjects: 402
Study 30570529 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 402
Study 29925489 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg)
Number of subjects: 563
Study 29925489 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir, Abacavir, Lamivudine
Number of subjects: 563
Study 27510017 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Number of subjects: 40
Study 27510017 — intervention group
Group type: COMPARATOR
Intervention: Diluted water (control)
Number of subjects: 40
Study 25415777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 32
Study 25415777 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 32
Study 22585774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dimenhydrinate (1 mg/kg; maximum: 50 mg) every 6 hours for 4 doses
Number of subjects: 144
Study 22585774 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 doses
Number of subjects: 144
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual snoring prevalence
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower family income
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower father's education
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration < 6 months
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy maternal smoking
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic/allergic rhinitis
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillar hypertrophy
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic otitis media
Number of subjects: 20152
Study 20955625 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of habitual snoring
Number of subjects: 20152
Study 17570789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic sparing (LS) technique with patent blue V dye (2 mL injected under the tunica dartos)
Number of subjects: 52
Study 17570789 — intervention group
Group type: COMPARATOR
Intervention: Lymphatic nonsparing (LNS) technique
Number of subjects: 52
Study 17570789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic sparing (LS) technique
Number of subjects: 52
Study 16279849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy (leaving a small thyroid remnant)
Number of subjects: 44
Study 16279849 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 44
Study 16279849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 44
Study 12376274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone injections at 10 mg
Number of subjects: 84
Study 12376274 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 84
Study 12376274 — intervention group
Group type: EXPERIMENTAL
Intervention: Total incidence of nausea and vomiting
Number of subjects: 84
Study 10553972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoleban EN (branched-chain amino acids) with normal diet for 12 weeks
Number of subjects: 50
Study 10553972 — intervention group
Group type: COMPARATOR
Intervention: Control group (isonitrogenous and isocaloric diet only)
Number of subjects: 50
Study 8672313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid progesterone concentration in the third trimester and term groups
Number of subjects: 134
Study 8672313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid progesterone concentration in the second trimester group
Number of subjects: 134
Study 8672313 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum cephalad spread of analgesia in the second trimester, third trimester, and term groups
Number of subjects: 134
Study 8672313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid progesterone concentration
Number of subjects: 134
Study 2177614 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 10
Study 2177614 — intervention group
Group type: COMPARATOR
Intervention: Control (no GM-CSF)
Number of subjects: 10
Study 7437265 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dapsone (DDS) + 25 mg pyrimethamine (PYR)
Number of subjects: 7
Study 7437265 — intervention group
Group type: COMPARATOR
Intervention: 100 mg dapsone (DDS)
Number of subjects: 7
Study 7437265 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies of plasma protein DDS binding
Number of subjects: 7
Study 30267864 — intervention group
Group type: COMPARATOR
Intervention: Infliximab monotherapy (5 mg/kg)
Number of subjects: 206
Study 30267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with infliximab and azathioprine (2.5 mg/kg/day)
Number of subjects: 206
Study 30267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with infliximab and azathioprine
Number of subjects: 206
Study 30267864 — intervention group
Group type: COMPARATOR
Intervention: Infliximab monotherapy
Number of subjects: 206
Study 28648969 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Self-Help (GENERIC)
Number of subjects: 2900
Study 28648969 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarette Targeted Self-Help (eTARGET)
Number of subjects: 2900
Study 28648969 — intervention group
Group type: COMPARATOR
Intervention: Assessment Only (ASSESS)
Number of subjects: 2900
Study 25598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 2089
Study 23288282 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy (true stimulation)
Number of subjects: 125
Study 23288282 — intervention group
Group type: COMPARATOR
Intervention: Sham auriculotherapy (placebo)
Number of subjects: 125
Study 21335787 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical practice (simulation training group)
Number of subjects: 24
Study 21335787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 21335787 — intervention group
Group type: COMPARATOR
Intervention: Knowledge retention alone group (listening to the didactic lesson without training)
Number of subjects: 24
Study 19756557 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 482
Study 19756557 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 482
Study 17903626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 238
Study 17903626 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 238
Study 15459609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment combined with streptokinase (HBO+)
Number of subjects: 74
Study 15459609 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase alone (HBO‐)
Number of subjects: 74
Study 11189826 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mailed intervention informing about Medicare mammogram benefits
Number of subjects: 1839
Study 11189826 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated cohorts)
Number of subjects: 1839
Study 9261526 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH)
Number of subjects: 151
Study 8290669 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 13
Study 8290669 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (short-term)
Number of subjects: 13
Study 8290669 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (long-term)
Number of subjects: 13
Study 8290669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2964548 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐10‐hydroxy‐NT
Number of subjects: 8
Study 2964548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 8
Study 2964548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2964548 — intervention group
Group type: EXPERIMENTAL
Intervention: NA infusion
Number of subjects: 8
Study 2964548 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐10‐hydroxy‐NT and NT
Number of subjects: 8
Study 31526307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (1 mg/g of body weight)
Number of subjects: 100
Study 31526307 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate
Number of subjects: 100
Study 29173128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT) plus an individually tailored intervention module focused on cognitive conflicts (CCs)
Number of subjects: 104
Study 29173128 — intervention group
Group type: COMPARATOR
Intervention: Group plus individual CBT
Number of subjects: 104
Study 28391619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 0
Study 28391619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (for patients with large lesions ≥ 20 cm2)
Number of subjects: 0
Study 28391619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (for the majority of patients with smaller lesions)
Number of subjects: 0
Study 28391619 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study 25916088 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 14
Study 25916088 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 14
Study 23834159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-reduced diet (FRD) for 4 weeks after a 2-week run-in on IBS diet
Number of subjects: 182
Study 23834159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fructose-reduced diet)
Number of subjects: 182
Study 23834159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose breath test (FBT)
Number of subjects: 182
Study 20705795 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based plus video training
Number of subjects: 47
Study 20705795 — intervention group
Group type: COMPARATOR
Intervention: Video training alone
Number of subjects: 47
Study 20705795 — intervention group
Group type: EXPERIMENTAL
Intervention: MICU (post-intervention)
Number of subjects: 47
Study 20705795 — intervention group
Group type: COMPARATOR
Intervention: SICU (no intervention)
Number of subjects: 47
Study 20705795 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention MICU
Number of subjects: 47
Study 19499865 — intervention group
Group type: EXPERIMENTAL
Intervention: Coopdech blocker
Number of subjects: 120
Study 19499865 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt blocker
Number of subjects: 120
Study 19499865 — intervention group
Group type: EXPERIMENTAL
Intervention: Univent tube
Number of subjects: 120
Study 19499865 — intervention group
Group type: COMPARATOR
Intervention: double-lumen tube
Number of subjects: 120
Study 16690968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab/CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 362
Study 15533586 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated IFG
Number of subjects: 627
Study 15533586 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated IGT
Number of subjects: 627
Study 15533586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFG and IGT
Number of subjects: 627
Study 11136953 — intervention group
Group type: COMPARATOR
Intervention: DASH diet with high sodium
Number of subjects: 412
Study 11136953 — intervention group
Group type: COMPARATOR
Intervention: DASH diet with low sodium
Number of subjects: 412
Study 11136953 — intervention group
Group type: COMPARATOR
Intervention: Control diet with high sodium to intermediate sodium
Number of subjects: 412
Study 11136953 — intervention group
Group type: COMPARATOR
Intervention: Control diet with intermediate sodium to low sodium
Number of subjects: 412
Study 11136953 — intervention group
Group type: COMPARATOR
Intervention: DASH diet with intermediate sodium to low sodium
Number of subjects: 412
Study 11136953 — intervention group
Group type: COMPARATOR
Intervention: DASH diet with high sodium to intermediate sodium
Number of subjects: 412
Study 9630383 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarines enriched in soybean oil sterol‐esters
Number of subjects: 100
Study 9630383 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarines enriched in sitostanol‐ester
Number of subjects: 100
Study 9630383 — intervention group
Group type: COMPARATOR
Intervention: Control margarine (non‐enriched)
Number of subjects: 100
Study 7530697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of L-697,639 (25 mg to 500 mg)
Number of subjects: 0
Study 7530697 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of L-697,639 (up to 100 mg every 12 h for ten days)
Number of subjects: 0
Study 7530697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of L-697,639 (200 mg and 500 mg)
Number of subjects: 0
Study 7530697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of L-697,639 (25 mg and 500 mg)
Number of subjects: 0
Study 7530697 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of L-697,639
Number of subjects: 0
Study 7530697 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg dose of L-697,639
Number of subjects: 0
Study 3042150 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Number of subjects: 300
Study 3042150 — intervention group
Group type: COMPARATOR
Intervention: Bed rest for 6 hours (3 hours prone followed by 3 hours supine)
Number of subjects: 300
Study 30658270 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fetal attachment (MFA)
Number of subjects: 36
Study 30658270 — intervention group
Group type: COMPARATOR
Intervention: Maternal depression
Number of subjects: 36
Study 30658270 — intervention group
Group type: COMPARATOR
Intervention: Parenting stress
Number of subjects: 36
Study 28750610 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + BCAA
Number of subjects: 0
Study 28750610 — intervention group
Group type: COMPARATOR
Intervention: CR
Number of subjects: 0
Study 28750610 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA without CR
Number of subjects: 0
Study 26359611 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based staff training programme delivered by a small intervention team
Number of subjects: 40
Study 26359611 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 22329426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadness mood induction
Number of subjects: 300
Study 22329426 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame mood induction
Number of subjects: 300
Study 22329426 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 300
Study 21839410 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper version of the PRO instrument
Number of subjects: 0
Study 21839410 — intervention group
Group type: EXPERIMENTAL
Intervention: Web version of the PRO instrument
Number of subjects: 0
Study 21839410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response system version of the PRO instrument
Number of subjects: 0
Study 21839410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview version of the PRO instrument
Number of subjects: 0